Scarica l'app Stockscreener
26.71
2.77%
-0.76
Dopo l'orario di chiusura:
26.77
0.06
+0.22%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$27.47
Aprire:
$27.2
Volume 24 ore:
10.12M
Relative Volume:
0.95
Capitalizzazione di mercato:
$10.33B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-3.0596
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
-16.92%
1M Prestazione:
-12.40%
6M Prestazione:
-20.53%
1 anno Prestazione:
-67.55%
Intervallo 1D:
$26.32
$27.48
Intervallo di 1 settimana:
$26.32
$31.84
Portata 52W:
$23.15
$91.99
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
26.71 | 10.69B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.65 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.13 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
428.14 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.15 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
298.52 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
RFK Jr. ends mRNA vaccine support; Moderna, other Mass. firms affected - WCVB
US HHS cancels 22 BARDA mRNA vaccine contracts - BioWorld MedTech
Public health experts dismayed by RFK Jr.'s defunding of mRNA vaccine research : ShotsHealth News - NPR
Moderna’s stock takes a hit as RFK Jr. backs out of some mRNA vaccine deals - MarketWatch
US health agency to wind down mRNA vaccine development - Reuters
The intrapreneur edge: What we learned at Moderna about the need to act like a startup - The Globe and Mail
Robust Growth in Mrna Therapeutics Process Development Market - openPR.com
RFK Jr. Axes 22 mRNA Vaccine Projects Under BARDA - BioSpace
ABC Arbitrage SA Takes Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
HHS halts funding for mRNA vaccine activities (MRNA:NASDAQ) - Seeking Alpha
RFK Jr. Halts $500 Million In mRNA Vaccine Projects Backed By Pfizer, Moderna: 'We're Prioritizing Safer, Broader Strategies' - Benzinga
Moderna Stock: Is Wall Street Bullish or Bearish? - Yahoo Finance
Envestnet Asset Management Inc. Sells 12,212 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Pfizer, Sanofi In Focus As US Winds Down mRNA Vaccine Plans; Retail Turns Bearish On AstraZeneca - MSN
Wealthquest Corp Buys Shares of 36,587 Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
US Health Department Pulls Back on Funding mRNA Vaccine Research - Bloomberg.com
14,589 Shares in Moderna, Inc. (NASDAQ:MRNA) Purchased by Banque Cantonale Vaudoise - MarketBeat
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease - Milwaukee Journal Sentinel
Barclays Has Lowered Expectations for Moderna (NASDAQ:MRNA) Stock Price - MarketBeat
Moderna: RSV Upside Slim, Cash Burn Heavy (NASDAQ:MRNA) - Seeking Alpha
Let’s make a deal? Big Pharma execs express varying views on their M&A future - PharmaVoice
Lipid Nanoparticles Market Industry Trends, Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2034 - GlobeNewswire Inc.
Zurcher Kantonalbank Zurich Cantonalbank Sells 134,443 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Holdings Cut by Pacer Advisors Inc. - MarketBeat
Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1 - The Florida Times-Union
UK Court of Appeal Confirms Moderna’s EP’949 Patent is Valid and Infringed by Pfizer/BioNTech - Pocono Record
Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates - Lohud
Moderna Seeks To Be Cleared In $5B COVID Vax Patent Case - Law360
BofA Securities lowers Moderna stock price target to $24 on COVID reliance - Investing.com
EU regulator backs Moderna's updated COVID vaccine - MSN
Moderna Tops Vaccine Expectations But Trims Future Outlook - Finimize
Moderna stock falls as UBS reiterates Buy rating amid cost cuts - Investing.com Canada
How the U.S. mRNA Therapeutics Market Will Evolve by 2032 - openPR.com
Moderna Q2 Earnings Review: Downsizing Triggers Selloff, But I'm Long-Term Bullish (MRNA) - Seeking Alpha
Moderna (NASDAQ:MRNA) Announces Quarterly Earnings Results - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Has $1.16 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
XTX Topco Ltd Raises Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
What is Moderna Inc. company’s growth strategyPowerful profit generation - Jammu Links News
Private Advisor Group LLC Sells 13,174 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
What markets is BLIV expanding into Is Moderna Inc. stock a good long term investment optionRapid capital growth - Jammu Links News
What analysts say about Moderna Inc. stockMaximize your portfolio’s growth potential - jammulinksnews.com
What institutional investors are buying Moderna Inc. stockAchieve rapid financial growth with expert help - Jammu Links News
Moderna: Is Now the Time to Buy the Deep Value Dip? - FXEmpire
Moderna’s Hold Rating: Navigating Revenue Adjustments and Product Development Uncertainties - TipRanks
What are Moderna Inc. company’s key revenue driversHigh-octane gains - jammulinksnews.com
Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio? - Benzinga
When is Moderna Inc. stock expected to show significant growthHigh-octane financial growth - Jammu Links News
Is Moderna Inc. a growth stock or a value stockBuild wealth faster with expert stock selection - Jammu Links News
Moderna, Inc. - Britannica
Letko Brosseau & Associates Inc. Has $25.41 Million Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Sees Unusually High Options Volume (NASDAQ:MRNA) - MarketBeat
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.10%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):